-
公开(公告)号：US20200375990A1
公开(公告)日：2020-12-03
申请号：US16924082
申请日：2020-07-08
发明人： Robert MCRAE , Gail L. BROWN , Xiaohu DENG , David SLACK , Marshelle Smith WARREN , Richard TRAUGER
IPC分类号： A61K31/506 , A61K31/522 , A61P35/00
摘要： Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
-
公开(公告)号：US20230113598A1
公开(公告)日：2023-04-13
申请号：US17814224
申请日：2022-07-21
发明人： Joseph ARNDT , Timothy Chan , Kevin Guckian , Gnanasambandam Kumaravel , Wen-Cheng Lee , Edward Yin-Shiang Lin , Daniel Scott , Lihong Sun , Jermaine Thomas , Kurt Van Vloten , Deping Wang , Lei Zhang , Daniel Erlanson
IPC分类号： C07D471/04 , C07D213/82 , C07D213/85 , C07D241/26 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D417/14 , C07D473/34 , C07D487/04 , C07D491/052 , C07D519/00 , C07D241/28 , C07D498/04 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/452 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/5383
摘要： The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
-
公开(公告)号：US10857152B2
公开(公告)日：2020-12-08
申请号：US15959482
申请日：2018-04-23
IPC分类号： A61K31/506 , A61K31/52 , A61K31/522 , A61K31/167 , A61K31/19 , A61K31/27 , A61K31/4045 , A61K31/513 , A61K45/06 , A61K38/12 , A61K31/18 , A61K9/00 , A61K31/165 , A61K31/473 , A61K31/4402 , A61K38/15
摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
-
公开(公告)号：US20200368280A1
公开(公告)日：2020-11-26
申请号：US16961200
申请日：2019-01-11
发明人： Marshelle WARREN , Preston DANIELS
IPC分类号： A61K35/17 , A61P35/02 , A61K31/506 , A61K39/395 , A61P31/18 , C12N5/0783
摘要： Described herein are methods and compositions useful for augmenting cell-based immunotherapies. The augmented cell-based immunotherapies can be used to treat individuals with cancer and chronic viral infections.
-
公开(公告)号：US20240342172A1
公开(公告)日：2024-10-17
申请号：US17314550
申请日：2021-05-07
IPC分类号： A61K31/506 , A61K9/00 , A61K31/165 , A61K31/167 , A61K31/18 , A61K31/19 , A61K31/27 , A61K31/4045 , A61K31/4402 , A61K31/473 , A61K31/513 , A61K31/52 , A61K31/522 , A61K38/12 , A61K38/15 , A61K45/06
CPC分类号： A61K31/506 , A61K9/0053 , A61K31/165 , A61K31/167 , A61K31/18 , A61K31/19 , A61K31/27 , A61K31/4045 , A61K31/4402 , A61K31/473 , A61K31/513 , A61K31/52 , A61K31/522 , A61K38/12 , A61K38/15 , A61K45/06 , Y02A50/30
摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
-
公开(公告)号：US20230099829A1
公开(公告)日：2023-03-30
申请号：US17831041
申请日：2022-06-02
发明人： Stig K. HANSEN , Minke E. BINNERTS
IPC分类号： A61K31/497 , A61K31/506 , A61K31/444 , A61K31/4439 , A61K31/519 , A61K31/517 , A61P35/02
摘要： Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.
-
公开(公告)号：US20240246988A1
公开(公告)日：2024-07-25
申请号：US18505940
申请日：2023-11-09
发明人： Minna BUI , Patrick R. CONLON , Julio H. CUERVO , Daniel A. ERLANSON , Junfa FAN , Bing GUAN , Brian T. HOPKINS , Tracy J. JENKINS , Gnanasambandam KUMARAVEL , Alexey A. LUGOVSKOY , Doug MARCOTTE , Noel POWELL , Daniel SCOTT , Laura SILVIAN , Art TAVERAS , Deping WANG , Min ZHONG
IPC分类号： C07D487/14 , A61K31/519 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/34 , C07D487/04
CPC分类号： C07D487/14 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/34 , C07D487/04 , A61K31/519
摘要： The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
-
公开(公告)号：US20240207258A1
公开(公告)日：2024-06-27
申请号：US18600974
申请日：2024-03-11
发明人： Stig K. HANSEN , Minke E. BINNERTS
IPC分类号： A61K31/497 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/517 , A61K31/519 , A61P35/02
CPC分类号： A61K31/497 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/517 , A61K31/519 , A61P35/02
摘要： Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.
-
公开(公告)号：US20240058347A1
公开(公告)日：2024-02-22
申请号：US17766643
申请日：2020-10-06
IPC分类号： A61K31/522 , A61K31/506 , A61P35/00
CPC分类号： A61K31/522 , A61K31/506 , A61P35/00
摘要： Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
-
公开(公告)号：US20220249477A1
公开(公告)日：2022-08-11
申请号：US17545217
申请日：2021-12-08
IPC分类号： A61K31/506 , A61K31/167 , A61K31/19 , A61K31/27 , A61K31/4045 , A61K31/513 , A61K45/06 , A61K31/52 , A61K38/12 , A61K31/18 , A61K9/00 , A61K31/165 , A61K31/473 , A61K31/522 , A61K31/4402 , A61K38/15
摘要： Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.017 秒)
